Efficacy and safety of rituximab for primary membranous nephropathy with different clinical presentations: a retrospective study.

Zhang, Shasha; Huang, Jing; Dong, Jianwei; Li, Zhuo; Sun, Mengyao; Sun, Yujiao; Chen, Bing

Zhang, Shasha; Huang, Jing; Dong, Jianwei; Li, Zhuo; Sun, Mengyao; Sun, Yujiao; Chen, Bing.

Affiliation

Zhang S; Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Huang J; Department of Nephrology, Jinan Shizhong People's Hospital, Jinan, China.
Dong J; Department of Thoracic Surgery, The People's Hospital of Rongcheng, Rongcheng, Shandong, China.
Li Z; Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Sun M; Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Sun Y; Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Chen B; Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.

Front Immunol ; 14: 1156470, 2023.

Article in En | MEDLINE | ID: mdl-37187749

Subject(s)
Key words

anti-PLA2R antibody; clinical remission rate; primary membranous nephropathy; rituximab; safety

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Glomerulonephritis, Membranous Type of study: Diagnostic_studies / Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Front Immunol Year: 2023 Document type: Article Affiliation country: China Country of publication: Suiza

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google